BusinessWorld Online reports Eli Lilly is cutting the price of a weight loss drug

More peptides

1. Generic semaglutide makes up 74% of India's volume six months after patent expiry

   FFacebook Oct 21

   peptides typeshitPrices

   Generic semaglutide makes up 74% of India's volume six months after patent expiry

   Monthly units climbed from 114,000 in February to 434,000 in September, and sales value rose from ₹48 cr to ₹113 cr as doctors report wider access.

   See it on Facebook
2. Australian researchers weigh whether subsidizing GLP-1 drugs would make care fairer

   

   MXMedical Xpress Oct 21

   peptides typeshitPrices

   Australian researchers weigh whether subsidizing GLP-1 drugs would make care fairer

   Access to Ozempic, Wegovy and Mounjaro in Australia often comes down to who can pay, raising the question of public subsidies.

   Read at Medical Xpress
3. Ozempic and Mounjaro brought in $71B last year, more than OpenAI and Anthropic

   

   H@HealthcareAIGuy Oct 20

   peptides typeshitPrices

   Ozempic and Mounjaro brought in $71B last year, more than OpenAI and Anthropic

   HealthcareAIGuy says the two drugs earned about four times the AI labs' combined revenue, while only around 2% of people with obesity worldwide take them.

   See it on X
4. Simply Wall St weighs Novo Nordisk's outlook as Lilly and Viking competition grows

   

   YFYahoo Finance Oct 20

   peptides typeshitPrices

   Simply Wall St weighs Novo Nordisk's outlook as Lilly and Viking competition grows

   The analysis points to CagriSema filings, a DKK 15b buyback and Wegovy pill capacity, while flagging margin pressure and flat 2026 guidance as risks.

   Read at Yahoo Finance
5. Facebook explainer on weight loss drugs and heart attack and stroke risk

   

   FFacebook Oct 21

   peptides typeshitResearch

   Facebook explainer on weight loss drugs and heart attack and stroke risk

   A short social post says drugs like Ozempic may lower heart attack and stroke risk, possibly beyond what weight loss alone explains.

   See it on Facebook
6. ThePrint looks at GLP-1 users trying smaller doses to cut nausea and side effects

   

   TThePrintIndia Oct 21

   peptides typeshitSafety

   ThePrint looks at GLP-1 users trying smaller doses to cut nausea and side effects

   Some people on weight loss drugs are testing lower doses, hoping for fewer side effects. ThePrint reports on the trend, which these users describe themselves.

   See it on X